


Neural Therapies
Research Services • León, Castilla and Leon, Spain • 1-10 Employees
Company overview
| Headquarters | León, Castilla and Leon, Spain |
| Website | |
| SIC | 809 |
| Keywords | Research, Inflammation, Stroke, Parkinson, Animal Models |
| Founded | 2015 |
| Employees | 1-10 |
Key Contact at Neural Therapies
Arsenio Fernández López
CEO, founder and scientific advisor in Neural Therapies
Neural Therapies Email Formats
Neural Therapies uses 1 email format. The most common is {first initial}{second initial} (e.g., jo@neuraltherapies.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{second initial} | jo@neuraltherapies.com | 100% |
About Neural Therapies
Neural Therapies is a Contract Research Organisation (CRO) specialised in the analysis of the effect of drug candidates and/or nutraceuticals in preclinical rodent models of stroke and Alzheimer’s Disease. A customized analysis of the damage extension, different cell death pathways, homeostatic and/or behavioural response can be performed, assessed by a panel of experts to optimize costs and assays. Additional services extensive to other pathologies have been added to our portfolio. These services include toxicological analysis, immunofluorescence and confocal microscopy assays as well as stereology services. Located in Leon, Spain, Neural Therapies provides a cost-effective service, offering cutting-edge technology at reasonable price, and customizing each assay according to the client's need or request. Services Our technical skills and deep knowledge in biomedical research grant a customized design for each project to satisfy our customer needs. The main services included in our portfolio are: 1.- Molecule screening in the following stroke models: a. Middle cerebral artery occlusion (MCAO) model b. 2-vessel occlusion (2VO) model c. Oxygen and glucose deprivation (OGD) in organotypic hippocampal cultures Evaluation of the molecule effects includes infarct volume, behavioural response, astroglia/microglia dynamics and homeostatic pathways according to customer’s needs. 2.- Molecule screening in the following Alzheimer’s Disease models: a. PS1delta9 x APPlondon (PS1/APP) transgenic mice. Evaluation of the molecule effects includes beta-amyloid deposits, tau protein phosphorylation, neuroinflammation and behavioural analysis. 3.- Toxicological analyses in rodents: Evaluation of the toxic effects of the molecule includes number of blood cells, serum analysis of ALT, AST, CK and urea and collection and/or histopathological analysis of organs selected by the customer. 4.- Confocal microscopy-based analyses.
Neural Therapies revenue & valuation
| Annual revenue | $342,220 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Research Services industry and current estimated revenues | $1,100,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Neural Therapies has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
Neural Therapies has never raised funding before.
Neural Therapies Tech Stack
Discover the technologies and tools that power Neural Therapies's digital infrastructure, from frameworks to analytics platforms.
Web servers
Font scripts
JavaScript libraries
Programming languages
Miscellaneous
Blogs
Miscellaneous
Databases
Page builders
Cookie compliance
Performance
SEO
Frequently asked questions
4.8
40,000 users



